Neurotech International Limited: Finishes Recruitment for Phase II/III Autism Trial

Neurotech International Limited (ASX: NTI), specializing in paediatric neurological disorders, announces the successful recruitment completion for the Phase II/III NTIASD2 clinical trial, focusing on children diagnosed with autism spectrum disorder (ASD) Levels 2 and 3. The trial, enrolling 56 patients, operated at the Paediatric Neurology Unit in Monash Medical Centre under Professor Michael Fahey's supervision.

NTIASD2, a randomized, double-blind, placebo-controlled study, aims to assess NTI164's safety and effectiveness versus a placebo in up to 54 ASD patients. The trial spans an 8-week treatment, followed by an 8-week open-label maintenance period and a subsequent 2-week wash-out phase. Participants opting for continued NTI164 treatment post-study may extend for an additional 38 weeks, including a 2-week down-titration phase upon completion of the extension period.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com